Doxecitine

Doxecitine

SCHEMBL15832461

Nc1ccn([C@H]2CC(O)C(CO)O2)c(=O)n1

nearest known ligand 0.66

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNMT1 P26358 3/20 0.66
ADRB1 P08588 1/20 0.66
POLB P06746 1/20 0.62
LMNA P02545 5/20 0.62
THRB P10828 1/20 0.62
MTOR P42345 1/20 0.62
MDM2 Q00987 1/20 0.62
NCOA1 Q15788 1/20 0.62
NCOA3 Q9Y6Q9 1/20 0.62
PDE3A Q14432 4/20 0.59
CACNA1F O60840 2/20 0.59
ALB P02768 2/20 0.59
MAPT P10636 2/20 0.59
CACNA1D Q01668 2/20 0.59
CACNA1S Q13698 2/20 0.59
CACNA1C Q13936 2/20 0.59
PDE4D Q08499 2/20 0.58
SLC29A1 Q99808 1/20 0.58
P2RY2 P41231 3/20 0.51
P2RY4 P51582 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Doxecitine SCHEMBL29910618 1.00 DNMT1 (0.66) DNMT1ADRB1POLBLMNATHRB
Doxecitine SCHEMBL30616799 1.00 DNMT1 (0.66) DNMT1ADRB1POLBLMNATHRB
Doxecitine SCHEMBL887491 1.00 DNMT1 (0.66) DNMT1ADRB1POLBLMNATHRB
Doxecitine SCHEMBL10238960 1.00 DNMT1 (0.66) DNMT1ADRB1POLBLMNATHRB
Doxecitine SCHEMBL31503186 1.00 DNMT1 (0.66) DNMT1ADRB1POLBLMNATHRB
Doxecitine SCHEMBL23346798 1.00 DNMT1 (0.66) DNMT1ADRB1POLBLMNATHRB
Doxecitine SCHEMBL13700553 1.00 DNMT1 (0.66) DNMT1ADRB1POLBLMNATHRB
Doxecitine SCHEMBL23178 1.00 DNMT1 (0.66) DNMT1ADRB1POLBLMNATHRB
Doxecitine SCHEMBL193815 1.00 DNMT1 (0.66) DNMT1ADRB1POLBLMNATHRB
Doxecitine SCHEMBL2623809 1.00 DNMT1 (0.66) DNMT1ADRB1POLBLMNATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264969-A1 METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES OPHTHOTECH CORPORATION 2016-09-15 US disclosed
US-20140179621-A1 Methods for Treating or Preventing Ophthalmological Diseases OPHTHOTECH CORPORATION (US) 2014-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179621-A1 Methods for Treating or Preventing Ophthalmological Diseases VEGFA, PDGFA, PGF DNMT1 4130/4885ADRB1 1602/4885POLB 1529/4885
US-20160264969-A1 METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES VEGFA, PDGFA, PGF DNMT1 4130/4885ADRB1 1602/4885POLB 1529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.